Spinal Muscular Atrophy Therapeutic and Forecast Market
1 Introduction to Research & Analysis Reports
1.1 Spinal Muscular Atrophy (SMA) Therapeutic Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Spinal Muscular Atrophy (SMA) Therapeutic Overall Market Size
2.1 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size: 2021 VS 2028
2.2 Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Spinal Muscular Atrophy (SMA) Therapeutic Players in Global Market
3.2 Top Global Spinal Muscular Atrophy (SMA) Therapeutic Companies Ranked by Revenue
3.3 Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Companies
3.4 Top 3 and Top 5 Spinal Muscular Atrophy (SMA) Therapeutic Companies in Global Market, by Revenue in 2021
3.5 Global Companies Spinal Muscular Atrophy (SMA) Therapeutic Product Type
3.6 Tier 1, Tier 2 and Tier 3 Spinal Muscular Atrophy (SMA) Therapeutic Players in Global Market
3.6.1 List of Global Tier 1 Spinal Muscular Atrophy (SMA) Therapeutic Companies
3.6.2 List of Global Tier 2 and Tier 3 Spinal Muscular Atrophy (SMA) Therapeutic Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size Markets, 2021 & 2028
4.1.2 Nusinersen
4.1.3 Onasemnogen Abeparvovec
4.2 By Type - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue & Forecasts
4.2.1 By Type - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue, 2017-2022
4.2.2 By Type - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue, 2023-2028
4.2.3 By Type - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2021 & 2028
5.1.2 Type 1 SMA
5.1.3 Type 2 SMA
5.1.4 Other
5.2 By Application - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue & Forecasts
5.2.1 By Application - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue, 2017-2022
5.2.2 By Application - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue, 2023-2028
5.2.3 By Application - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2021 & 2028
6.2 By Region - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue & Forecasts
6.2.1 By Region - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue, 2017-2022
6.2.2 By Region - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue, 2023-2028
6.2.3 By Region - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue, 2017-2028
6.3.2 US Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.3.3 Canada Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.3.4 Mexico Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue, 2017-2028
6.4.2 Germany Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.4.3 France Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.4.4 U.K. Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.4.5 Italy Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.4.6 Russia Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.4.7 Nordic Countries Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.4.8 Benelux Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Spinal Muscular Atrophy (SMA) Therapeutic Revenue, 2017-2028
6.5.2 China Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.5.3 Japan Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.5.4 South Korea Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.5.5 Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.5.6 India Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue, 2017-2028
6.6.2 Brazil Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.6.3 Argentina Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue, 2017-2028
6.7.2 Turkey Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.7.3 Israel Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.7.4 Saudi Arabia Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
6.7.5 UAE Spinal Muscular Atrophy (SMA) Therapeutic Market Size, 2017-2028
7 Players Profiles
7.1 Biogen
7.1.1 Biogen Corporate Summary
7.1.2 Biogen Business Overview
7.1.3 Biogen Spinal Muscular Atrophy (SMA) Therapeutic Major Product Offerings
7.1.4 Biogen Spinal Muscular Atrophy (SMA) Therapeutic Revenue in Global Market (2017-2022)
7.1.5 Biogen Key News
7.2 Novartis
7.2.1 Novartis Corporate Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Spinal Muscular Atrophy (SMA) Therapeutic Major Product Offerings
7.2.4 Novartis Spinal Muscular Atrophy (SMA) Therapeutic Revenue in Global Market (2017-2022)
7.2.5 Novartis Key News
7.3 Roche
7.3.1 Roche Corporate Summary
7.3.2 Roche Business Overview
7.3.3 Roche Spinal Muscular Atrophy (SMA) Therapeutic Major Product Offerings
7.3.4 Roche Spinal Muscular Atrophy (SMA) Therapeutic Revenue in Global Market (2017-2022)
7.3.5 Roche Key News
7.4 Astellas Pharma
7.4.1 Astellas Pharma Corporate Summary
7.4.2 Astellas Pharma Business Overview
7.4.3 Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Major Product Offerings
7.4.4 Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Revenue in Global Market (2017-2022)
7.4.5 Astellas Pharma Key News
7.5 Genzyme Corporation
7.5.1 Genzyme Corporation Corporate Summary
7.5.2 Genzyme Corporation Business Overview
7.5.3 Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Major Product Offerings
7.5.4 Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Revenue in Global Market (2017-2022)
7.5.5 Genzyme Corporation Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Spinal Muscular Atrophy (SMA) Therapeutic Market Opportunities & Trends in Global Market
Table 2. Spinal Muscular Atrophy (SMA) Therapeutic Market Drivers in Global Market
Table 3. Spinal Muscular Atrophy (SMA) Therapeutic Market Restraints in Global Market
Table 4. Key Players of Spinal Muscular Atrophy (SMA) Therapeutic in Global Market
Table 5. Top Spinal Muscular Atrophy (SMA) Therapeutic Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Share by Companies, 2017-2022
Table 8. Global Companies Spinal Muscular Atrophy (SMA) Therapeutic Product Type
Table 9. List of Global Tier 1 Spinal Muscular Atrophy (SMA) Therapeutic Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Spinal Muscular Atrophy (SMA) Therapeutic Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Spinal Muscular Atrophy (SMA) Therapeutic Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Spinal Muscular Atrophy (SMA) Therapeutic Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Spinal Muscular Atrophy (SMA) Therapeutic Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Spinal Muscular Atrophy (SMA) Therapeutic Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2023-2028
Table 30. Biogen Corporate Summary
Table 31. Biogen Spinal Muscular Atrophy (SMA) Therapeutic Product Offerings
Table 32. Biogen Spinal Muscular Atrophy (SMA) Therapeutic Revenue (US$, Mn), (2017-2022)
Table 33. Novartis Corporate Summary
Table 34. Novartis Spinal Muscular Atrophy (SMA) Therapeutic Product Offerings
Table 35. Novartis Spinal Muscular Atrophy (SMA) Therapeutic Revenue (US$, Mn), (2017-2022)
Table 36. Roche Corporate Summary
Table 37. Roche Spinal Muscular Atrophy (SMA) Therapeutic Product Offerings
Table 38. Roche Spinal Muscular Atrophy (SMA) Therapeutic Revenue (US$, Mn), (2017-2022)
Table 39. Astellas Pharma Corporate Summary
Table 40. Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Product Offerings
Table 41. Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Revenue (US$, Mn), (2017-2022)
Table 42. Genzyme Corporation Corporate Summary
Table 43. Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Product Offerings
Table 44. Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Spinal Muscular Atrophy (SMA) Therapeutic Segment by Type in 2021
Figure 2. Spinal Muscular Atrophy (SMA) Therapeutic Segment by Application in 2021
Figure 3. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Spinal Muscular Atrophy (SMA) Therapeutic Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Spinal Muscular Atrophy (SMA) Therapeutic Revenue in 2021
Figure 8. By Type - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share, 2017-2028
Figure 9. By Application - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share, 2017-2028
Figure 10. By Region - Global Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share, 2017-2028
Figure 11. By Country - North America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share, 2017-2028
Figure 12. US Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share, 2017-2028
Figure 16. Germany Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 17. France Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share, 2017-2028
Figure 24. China Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 28. India Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share, 2017-2028
Figure 30. Brazil Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Spinal Muscular Atrophy (SMA) Therapeutic Revenue Market Share, 2017-2028
Figure 33. Turkey Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Spinal Muscular Atrophy (SMA) Therapeutic Revenue, (US$, Mn), 2017-2028
Figure 37. Biogen Spinal Muscular Atrophy (SMA) Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Novartis Spinal Muscular Atrophy (SMA) Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Roche Spinal Muscular Atrophy (SMA) Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Astellas Pharma Spinal Muscular Atrophy (SMA) Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Genzyme Corporation Spinal Muscular Atrophy (SMA) Therapeutic Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
